Evidence map›Paper›PMID 38932179›Full record

ArticleViruses2024

Findings and Challenges in Replacing Traditional Uterine Cervical Cancer Diagnosis with Molecular Tools in Private Gynecological Practice in Mexico.

José L Castrillo-Diez, Carolina Rivera-Santiago, Silvia M Ávila-Flores, Silvia A Barrera-Barrera, Hugo A Barrera-Saldaña

Abstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

José L Castrillo-DiezLeire Genomic Laboratories, León 37000, Mexico.
Carolina Rivera-SantiagoColumbia Biotec, Columbia Laboratories, Tlalpan 14090, Mexico.ORCID 0000-0001-9815-2667
Silvia M Ávila-FloresLeire Genomic Laboratories, León 37000, Mexico.
Silvia A Barrera-BarreraInnbiogem SC/Vitagenesis SA at National Laboratory for Services of Research, Development, and Innovation for the Pharma and Biotech Industries (LANSEIDI) of CONACyT Vitaxentrum Group, Monterrey 64630, Mexico.
Hugo A Barrera-SaldañaColumbia Laboratories, Basic Scientific Research Division, Mexico City 04000, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have been encouraging practicing gynecologists to adopt molecular diagnostics tests, PCR, and cancer biomarkers, as alternatives enabled by these platforms, to traditional Papanicolaou and colposcopy tests, respectively. An aliquot of liquid-based cytology was used for the molecular test [high-risk HPV types, (HR HPV)], another for the PAP test, and one more for p16/Ki67 dual-stain cytology. A total of 4499 laboratory samples were evaluated, and we found that 25.1% of low-grade samples and 47.9% of high-grade samples after PAP testing had a negative HR HPV-PCR result. In those cases, reported as Pap-negative, 22.1% had a positive HR HPV-PCR result. Dual staining with p16/Ki67 biomarkers in samples was positive for HR HPV, and 31.7% were also positive for these markers. Out of the PCR results that were positive for any of these HR HPV subtypes, n 68.3%, we did not find evidence for the presence of cancerous cells, highlighting the importance of performing dual staining with p16/Ki67 after PCR to avoid unnecessary colposcopies. The encountered challenges are a deep-rooted social reluctance in Mexico to abandon traditional Pap smears and the opinion of many specialists. Therefore, we still believe that colposcopy continues to be a preferred procedure over the dual-staining protocol.

Indexed as

Papillomavirus InfectionsUterine Cervical NeoplasmsAdultBiomarkers, TumorColposcopyCyclin-Dependent Kinase Inhibitor p16Early Detection of CancerFemaleGynecologyHumansKi-67 AntigenMexicoMiddle AgedMolecular Diagnostic TechniquesPapanicolaou TestPapillomaviridaeBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p16Ki-67 Antigengynecology private practiceHPV genotypingp16/Ki67 biomarkersuterine cervical cancer screening

Identifiers

PMID38932179
PMCPMC11209306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.